MX356347B - Anticuerpos humanos y secuencias de unión específicas de los mismos para su uso en apoplejía e isquemia o condiciones isquémicas. - Google Patents

Anticuerpos humanos y secuencias de unión específicas de los mismos para su uso en apoplejía e isquemia o condiciones isquémicas.

Info

Publication number
MX356347B
MX356347B MX2014012651A MX2014012651A MX356347B MX 356347 B MX356347 B MX 356347B MX 2014012651 A MX2014012651 A MX 2014012651A MX 2014012651 A MX2014012651 A MX 2014012651A MX 356347 B MX356347 B MX 356347B
Authority
MX
Mexico
Prior art keywords
antibodies
stroke
fragments
specific binding
human antibodies
Prior art date
Application number
MX2014012651A
Other languages
English (en)
Other versions
MX2014012651A (es
Inventor
Moses Rodriguez
Arthur E Warrington
Larry R Pease
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2014012651A publication Critical patent/MX2014012651A/es
Publication of MX356347B publication Critical patent/MX356347B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a miembros de unión específicos, en particular anticuerpos humanos, en particular anticuerpos recombinantes, y fragmentos de los mismos, los cuales son capaces de unirse a y reconocer neuronas en el SNC y de inducir respuestas en las neuronas del SNC; los anticuerpos son útiles en el diagnóstico y tratamiento de condiciones asociadas con daño, lesión o degeneración nerviosa y enfermedad neurodegenerativa, y en particular en el tratamiento o alivio de apoplejía o isquemia cerebral; los anticuerpos, regiones variables o secuencias del dominio de CDR de los mismos, y fragmentos de los mismos de la invención, pueden usarse también en terapia en combinación con quimioterapéuticos, inmunomoduladores o agentes neuroactivos y/o con otros anticuerpos o fragmentos de los mismos; los anticuerpos o fragmentos activos de los mismos pueden usarse en terapia para apoplejía o isquemia cerebral solos o en combinación con trombolíticos tales como TPA; los anticuerpos son ejemplificados por los anticuerpos lgM12 e lgM42, cuyas secuencias se proveen en la presente.
MX2014012651A 2012-04-17 2013-04-17 Anticuerpos humanos y secuencias de unión específicas de los mismos para su uso en apoplejía e isquemia o condiciones isquémicas. MX356347B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625628P 2012-04-17 2012-04-17
PCT/US2013/036947 WO2013158748A1 (en) 2012-04-17 2013-04-17 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions

Publications (2)

Publication Number Publication Date
MX2014012651A MX2014012651A (es) 2015-05-07
MX356347B true MX356347B (es) 2018-05-23

Family

ID=49384031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012651A MX356347B (es) 2012-04-17 2013-04-17 Anticuerpos humanos y secuencias de unión específicas de los mismos para su uso en apoplejía e isquemia o condiciones isquémicas.

Country Status (13)

Country Link
US (1) US20150104460A1 (es)
EP (2) EP3305323B1 (es)
JP (5) JP6162219B2 (es)
CN (2) CN108285483B (es)
BR (1) BR112014025898A2 (es)
CA (1) CA2870625C (es)
ES (2) ES2870717T3 (es)
HK (3) HK1206997A1 (es)
IL (2) IL235118B (es)
IN (1) IN2014MN02274A (es)
MX (1) MX356347B (es)
NZ (1) NZ701278A (es)
WO (1) WO2013158748A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
US11180543B2 (en) 2014-11-07 2021-11-23 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
US10787520B2 (en) 2015-03-04 2020-09-29 Igm Biosciences, Inc. Multimeric bispecific binding molecules specific for CD20 and CD3
CN108463245A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j链的结合分子
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
CN113444787A (zh) * 2021-07-05 2021-09-28 中山大学附属第七医院(深圳) 一种自闭症的脂质生物标志物及其应用
CN114276418A (zh) * 2021-12-28 2022-04-05 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2609494T3 (es) * 2000-05-10 2017-04-20 Mayo Foundation For Medical Education And Research Anticuerpos IgM humanos con la capacidad de inducir remielinización y usos diagnósticos y terapéuticos de los mismos, particularmente en el sistema nervioso central
PL1648427T3 (pl) 2003-05-16 2014-05-30 Mayo Found Medical Education & Res Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM
JP5452835B2 (ja) * 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるＩｇＭの産生とその定量方法
WO2006004988A2 (en) * 2004-06-30 2006-01-12 Mayo Foundation For Medical Education And Research B7-dc binding antibody
US7645575B2 (en) * 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
EP2007899B1 (en) * 2006-03-20 2017-06-07 Celldex Therapeutics, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
WO2009052374A2 (en) * 2007-10-18 2009-04-23 Mayo Foundation For Medical Education And Research Igm-mediated receptor clustering and cell modulation
JP2011523359A (ja) * 2008-05-13 2011-08-11 ジェネンテック， インコーポレイテッド 抗ＰｉｒＢ抗体
EP2621954A1 (en) * 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
EP2629795B1 (en) * 2010-10-19 2017-12-06 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US11180543B2 (en) * 2014-11-07 2021-11-23 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof

Also Published As

Publication number Publication date
IL266658B (en) 2021-04-29
IN2014MN02274A (es) 2015-08-07
CN108285483A (zh) 2018-07-17
MX2014012651A (es) 2015-05-07
HK1258380A1 (zh) 2019-11-08
EP3305323A1 (en) 2018-04-11
US20150104460A1 (en) 2015-04-16
HK1206997A1 (en) 2016-01-22
EP2838562A4 (en) 2015-09-30
EP3305323B1 (en) 2021-02-17
CN104379167B (zh) 2018-02-13
ES2655077T3 (es) 2018-02-16
CN104379167A (zh) 2015-02-25
IL235118A0 (en) 2014-12-31
CA2870625C (en) 2023-06-20
WO2013158748A1 (en) 2013-10-24
IL266658A (en) 2019-07-31
NZ701278A (en) 2016-12-23
JP2019050832A (ja) 2019-04-04
JP2021000120A (ja) 2021-01-07
EP2838562B1 (en) 2017-08-30
CN108285483B (zh) 2022-04-26
CA2870625A1 (en) 2013-10-24
BR112014025898A2 (pt) 2017-11-07
JP6162219B2 (ja) 2017-07-12
JP2022107016A (ja) 2022-07-20
HK1207565A1 (en) 2016-02-05
IL235118B (en) 2019-06-30
JP2017127329A (ja) 2017-07-27
EP2838562A1 (en) 2015-02-25
JP2015520608A (ja) 2015-07-23
ES2870717T3 (es) 2021-10-27

Similar Documents

Publication Publication Date Title
NZ701278A (en) Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
WO2012054077A3 (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
WO2014089169A3 (en) Immunotherapy with binding agents
MY169328A (en) Compositions for the treatment of dry eye
WO2016004389A3 (en) Monovalent binding proteins
IL237743A0 (en) A combination of rasagiline and pridofidine for the treatment of neurodegenerative diseases, and specifically for the treatment of Huntington's disease
BR112018009891A2 (pt) vesículas extracelulares de célula neural
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
PH12015500663A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
MX2015008117A (es) Anticuerpos anti-h7cr.
WO2016057726A3 (en) Human anti-vegfr-2/kdr antibodies
TH1601002196A (th) การใช้โมเลกุลที่ยึดจับเซมาโฟริน-4D สำหรับการบำบัดความผิดปกติของโรคที่มี การทำลายเซลล์ประสาทในสมอง (neurodegenerative disorder)
WO2014207534A3 (en) Bradykinin receptor modulators and use thereof

Legal Events

Date Code Title Description
FG Grant or registration